Discover the full directors' dealings record of LUMIBIRD, a publicly traded company based in France. Shares trade on FR FR, under the supervision of AMF. Operating in the Technology sector, LUMIBIRD has recorded 1 insider filings. Market capitalisation: €523m. The latest transaction was disclosed on 6 July 2023 — Cession. Among the most active insiders: ESIRA SAS - RCS Saint-Brieuc 533 467 841. The full history is openly available.
FY ended December 2025 · cache
1 of 1 declaration
LUMIBIRD is a French specialist in laser technologies and one of Europe’s leading laser groups. Listed on Euronext under the ticker LBIRD and identified by ISIN FR0000038242, the company designs, manufactures and markets laser systems and related subsystems for three main end markets: scientific research, industrial applications and medical uses. Its offering is built on three core laser technologies: solid-state lasers, laser diodes and fiber lasers. The group is particularly well positioned in ophthalmology, as well as in defense, LiDAR sensing and high-precision measurement applications. The group’s roots date back to 1997, when Marc Le Flohic founded Optocom Innovation, the company that later became Keopsys. LUMIBIRD first expanded through organic development, before accelerating its growth via acquisitions and mergers from 2014 onward. A defining milestone came in October 2017, when Keopsys and Quantel merged to create LUMIBIRD, establishing a European laser champion. The group then broadened its portfolio and geographic reach through acquisitions including Optotek Medical in 2019, Halo Photonics in 2019, Ellex Medical in 2020 and Convergent in 2023. Operationally, LUMIBIRD is organized around two complementary divisions. The Photonics division serves scientific, industrial and defense markets with high-performance laser sources, rangefinders, sensors and electro-optical systems. The Medical division brings together the Quantel Medical, Ellex and Optotek Medical brands, offering diagnostic and therapeutic laser solutions for ophthalmology. This structure gives the group a balanced exposure to different demand drivers, combining innovation-intensive niche markets with recurring medical applications and defense-related opportunities. LUMIBIRD operates an integrated industrial model, supported by research, manufacturing and sales capabilities across 14 countries. The company states that it employs around 1,000 people, with 12 R&D sites, 10 production sites and 15 commercial subsidiaries. Its historical base remains in Lannion, Brittany, but its industrial footprint and customer base are international. In 2025, the group reported annual revenue of €225.6 million, up 8.9% as reported and 10.2% at constant scope and exchange rates, confirming solid momentum across both divisions. A noteworthy feature of LUMIBIRD is its positioning in highly technical, innovation-driven markets where technological depth and industrial reliability are critical competitive advantages. The group has also highlighted defense-related contract wins in 2025 and 2026, underscoring the increasing strategic importance of this segment within its revenue mix. Overall, LUMIBIRD combines a strong French industrial heritage, a global commercial footprint and a differentiated expertise in laser technologies.